Target intelligence / Profile preview

Mastermind-like protein (MAML)

Target
MAML
Molecular classification
Transcription factor, Other
01

Overview

Mastermind-like (MAML) proteins, including MAML1, MAML2, and MAML3, are a family of transcriptional coactivators essential for the canonical Notch signaling pathway. Upon ligand binding, the Notch intracellular domain (NICD) translocates to the nucleus, where it binds the DNA-binding protein RBPJ (CSL) and recruits MAML to form a stable, active tripartite transcription complex. This complex subsequently recruits other coactivators, such as p300, to initiate the transcription of Notch target genes involved in cell fate determination, proliferation, and survival. Beyond Notch signaling, MAML proteins also function as coactivators in other major pathways, including Wnt/beta-catenin, Sonic Hedgehog, Hippo, and NF-kB.

Dysregulation of MAML proteins is strongly implicated in various human malignancies, such as T-cell acute lymphoblastic leukemia (T-ALL), breast cancer, and mucoepidermoid carcinoma, where recurrent MAML2 gene fusions (e.g., CRTC1-MAML2) act as oncogenic drivers. Consequently, MAML has emerged as an attractive therapeutic target. Pharmacological strategies to inhibit MAML include stapled peptides like SAHM1, which mimic dominant-negative MAML to block the assembly of the Notch transcription complex, and small molecules like IMR-1 that prevent MAML recruitment to chromatin. While targeting MAML offers a way to bypass the resistance and some toxicities associated with upstream gamma-secretase inhibitors, potential safety concerns include gastrointestinal toxicity, impaired myogenesis, and immune system disruption.

Other names
Mastermind-likeMastermind-like proteinMastermind-like transcriptional coactivatorMamMam-likeMAML1MAML2MAML3
02

Mechanism of action

Inhibition of the assembly of the Notch transcriptional activation complex (NTC) by disrupting the interaction between Mastermind-like (MAML) proteins, the Notch intracellular domain (NICD), and the DNA-binding protein RBPJ (CSL).

03

Biological functions

Signal transductionCell cycleApoptosisCell proliferationCell differentiationOther
04

Disease associations

CancerInflammationOther
05

Safety considerations

Gastrointestinal toxicity (e.g., severe diarrhea, goblet cell metaplasia) due to systemic Notch pathway inhibitionImpaired myogenesis or muscle regeneration (muscular dystrophy-like phenotypes)Impaired immune cell development (e.g., splenic marginal zone B cells and early thymocytes)Potential for vascular remodeling defects or cardiovascular toxicity
06

Interacting drugs

SAHM1

3 more in the full profile.

07

Biomarkers

NOTCH1 mutationNOTCH2 mutationNOTCH3 mutationCRTC1-MAML2 fusionCRTC3-MAML2 fusionYAP1-MAML2 fusionKMT2A-MAML2 fusionHES1 expressionHEY1 expressionMYC expression

Beyond the preview

Go deeper on Mastermind-like protein (MAML).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mastermind-like protein (MAML).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call